December 31, 2023, which was filed with the SEC in April 2024. You can find this under Note 14 – Related Party Transactions (it may be labeled Note 15 or 16 in the preliminary draft, but "Note 14" is the standard for this filing). The Direct Quote: "During the year ended December 31, 2023, the Company entered into an agreement to acquire the outstanding shares of Revimmune Limited for a nominal purchase price of $1.00. Revimmune Limited is a related party as it is owned by the Company’s CEO."
There is no such quote in 10-K. There is no mention of Revimmune anywhere in it. The Relatey Party Section is short, try actually reading it.